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Results
Median FU was 36 months and 25% of patients had a FU of at least 
60 months. The 5y-CIf of cGVHD was 58%. Sex mismatch (F>M) 
increased risk of cGVHD (HR: 1.41, P=.02). The 5y-CIf of relapse was 
34% and was higher with MRD than MUD (39% vs. 24%, P=.038). 
Only MRD=60y resulted in significant higher risk of relapse than 
MUD (HR 2.46, P=.006) while MRD <60y had similar risk. The 
5y-NRM was 26%. MUD vs. MRD was associated with higher NRM 
(HR: 1.84, P=.005). The 5y-OS was 46% and was similar with MUD and 
MRD. MRD=60y appeared to have notable low 5y-OS (6%, 6%). 
Transplantation from MRD=60y was associated with higher risk of 
late (=18 months) mortality (HR: 4.36, P=.007) than MUD (Fig. 1).
Conclusion
After PB SCT, MUD provided higher NRM but better disease control 
and similar OS than MRD. A sex mismatched donor (F>M) was 
associated with higher risk of cGVHD. We observed notable poor 
outcome for patients transplanted with MRD=60y. One may thus 
question HCT with old MRD when a younger MUD is available.
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Background
Chronic graft-versus-host disease (cGvHD) occurs up to 50 % in 
long-term survivors and is one of the main complications after allo-
HSCT. Donor CD4+ and regulatory T cells (Tregs) are the key-players 
in its pathogenesis. Moreover, rapamycin, a mTor inhibitor, could 
suppress activation and proliferation of effector T cells and expand 
in vitro Tregs.
Aims
To assess the combined treatment of Tregs and rapamycin injections 
in vivo for cGvHD.
Results
Lethally irradiated Balb/C mice were injected with 10x106 bone 
marrow cells and 70x106 splenocytes from B10.D2 donor mice. 
Twenty-one days later, the treatments were started (PBS, rapamycin 
1 mg/kg/Day, Tregs 1.106 cells or rapamycin 1 mg/kg/Day + Tregs 
1.106 cells). No significant differences were observed between 
survival of PBS-treated (Median: 40 days) compared to rapamycin 
alone or Tregs alone (Median: 46 days, p=0.1390; Median: 46 days, 
p=0.2450 respectively) while survival of mice receiving rapamycin 
and Tregs was increased (p=0.0074). Twenty-one days after starting 
the treatment, number of CD4+ T cells was significantly decreased 
in Tregs (37.0010.00; p=0.0303) and Tregs + rapamycin-treated 
(27.0056.00; p=0.0293) mice compared to PBS mice (95.00100.50). 
Proliferation of CD4+ T cells (assessed by flow cytometry unsing 
Ki67) was only significantly decreased in Tregs + rapamycin-treated 
mice (19.609.17 versus 36.8012.40; p=0.0043). Number of cells per 
micorliters and proliferation of both effector and central memory 
CD4+ T cells were significantly decreased in Tregs + rapamycin-treated 
mice compared to PBS mice. Number of CD8+ T cells was significantly 
decreased in rapamycin (56.0063.00; p=0.0082) and Tregs + rapamycin-
treated (58.5077.80; p=0.0082) mice compared to PBS mice 
(144.00103.80). Despite a significant increase in the percentage of 
Tregs in rapamycin 1 mg/kg/Day (20.3043.15; p=0.0519), Tregs 1.106 
cells (95.6559.75; p=0.0190) or rapamycin 1 mg/kg/Day + Tregs 1.106 
cells groups (29.6066.30; p=0.0043) compared to PBS-treated mice 
(15.353.80), no significant differences were seen in the number per 
micorliter.
Conclusion
Regulatory T cells injection combined with rapamycin daily 
administration seems to treat cGvHD in vivo by combining the 
beneficial effect of these treatments.
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Introduction
Transfer of high-affinity tumor-specific T-cell receptor (TCR) genes 
into polyclonal peripheral blood T-cells is an attractive immuno-
therapeutic strategy against malignancies and viruses. However, 
inappropriate crosspairing between introduced and endogenous 
TCR chains can result in suboptimal activity and unpredicted, 
potentially harmful antigen-specificities. Efficient in vitro generation 
of antigen-specific T-cells from CD34+ hematopoietic progenitor 
cells (HPCs) may eliminate these restrictions, based on the 
hypothesis that early introduction of rearranged TCRa and TCR 
chains might result in allelic exclusion of the endogenous TCRa 
and/or TCR locus. We and others have previously shown that HPCs 
commit to the T-cell lineage and become CD4+CD8+ double positive 
(DP) precursors when cultured on OP9-DL1 stromal cells.
Results
CD34+ HPCs from human postnatal thymus were retrovirally 
transduced to express the TCRa and TCR chains of HLA-A2 restricted 
TCRs recognising epitopes of cytomegalovirus (CMV pp65) or 
Wilms’ tumour 1 (WT1). Differentiation in transduced cultures was 
studied. We confirmed earlier reports showing that terminal 
maturation of TCR-transduced DP cells to mature CD8 single 
positive (SP) cells occurs, albeit at low efficiency. We hypothesised 
that the observed maturation involved selection by TCR binding to 
HLA class I /peptide complexes present in culture. Therefore, we 
added the respective agonist peptide to the cultures. This induced 
rapid phenotypical maturation to CD27+CD1- of the majority of TCRa+ 
DP cells. Antigen presentation by HLA-A2+ dendritic cells, HLA-A2+ 
tumour cell lines, and even cross-presentation by HLA-A2+ T-cell 
progenitors, but not by HLA-A2- cells, induced this maturation process.
The mature cells are CD8a+ or CD8aa+SP and CD4-CD8- cells. These 
T-cells expanded upon culture with PHA and IL-2 on irradiated 
feeders, indicating functionality. Upon activation, specific killing of 
T2 cells loaded with agonist peptide, was observed. In vitro 
generated T-cells showed clearly higher percentages of tetramer-
positive cells compared with TCR-transduced peripheral blood 
T-cells. Spectratyping revealed major inhibition of endogenous 
TCRa and TCR gene rearrangements.
Conclusion
In vitro generation of functional antigen-specific T-cells from CD34+ 
HPCs is a promising new immunotherapeutic strategy.
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